PacBio appoints Chris Smith to board

By Bobby Samwell • Thursday, January 30 15:44 • Permanent Link

PacBio (NASDAQ: PACB) has announced the appointment of Chris Smith to its board of directors, effective immediately. Chris Smith, the current CEO of NeoGenomics, Inc. (NASDAQ: NEO), brings extensive experience in the life sciences and healthcare industries, particularly in genomics, diagnostics, and corporate strategy. Prior to NeoGenomics, Smith served as the chairman and CEO of Ortho Clinical Diagnostics and as CEO of Cochlear Limited. He holds a Bachelor of Science degree in journalism from Texas A&M University.

Simultaneously, the company also announced the resignation of David Meline from the board. Meline had been a valued member since 2023 and played an important role in driving the business and strategy of the company.

PacBio, a leading developer of high-quality, highly accurate sequencing solutions, is currently focused on expanding into the clinical genomics market. The company's products and technologies, including Hifi long-read sequencing and SBB® short-read sequencing, cater to a wide range of research applications, such as human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Today the company's shares have moved 0.6% to a price of $1.57. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.